Saturday 17 October 2026
Export SLS’s income statement to Excel — free account
SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $1.0 million. In the quarter to June 2026, EPS grew 28.6% and free cash flow fell 3.52%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
9.98
1.36
−11.99%
Follow SLS
SELLAS Life Sciences Group, Inc. (SLS) P/E ratio
SELLAS Life Sciences Group, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 2.7× (December 2020) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2022 | 0.0× | — |
| Jun 2021 | 0.0× | — |
| Mar 2021 | 0.0× | — |
| Dec 2020 | 0.0× | — |
Against its own ten years
Low 0.0×
High 2.7×
Ten-year median
0.0×
Current reading's percentile
96
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| IRON Disc Medicine, Inc. compare | n/m |
| VRDN Viridian Therapeutics, Inc. compare | n/m |
| SLS SELLAS Life Sciences Group, Inc. | n/m |
| FTRE Fortrea Holdings Inc. compare | n/m |
| RXRX Recursion Pharmaceuticals, Inc. compare | n/m |
| CLDX Celldex Therapeutics, Inc. compare | n/m |
| AUPH Aurinia Pharmaceuticals Inc compare | 6.9× |
| HRMY Harmony Biosciences Holdings, Inc. compare | 12.2× |
| ADMA ADMA Biologics Inc compare | 14.8× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)